# Taiho Oncology, Inc. clinical trials: 66 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 66 trials with Taiho Oncology, Inc. as lead sponsor, 7 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Taiho Oncology, Inc.: 66 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/taiho-oncology-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 66
- Recruiting or not yet: 7
- Read on: November 19, 2026

## Trials

The 25 newest of 66, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 9, 2026 | NCT07691606 | A Study of ARC-02 in B-cell NHL | Taiho Oncology, Inc. | Phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691606) |
| May 22, 2026 | NCT07601399 | An EAP Treatment Protocol of Zipalertinib | Taiho Oncology, Inc. | Not applicable | Available | Non-Small Cell Lung Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601399) |
| August 17, 2025 | NCT07128199 | A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor... | Taiho Oncology, Inc. | Phase 3 | Recruiting | Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations, NSCLC, Early... | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128199) |
| July 18, 2024 | NCT06506955 | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | Taiho Oncology, Inc. | Phase 2/3 | Active not recruiting | Advanced/Metastatic Cancer | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06506955) |
| August 3, 2023 | NCT05973773 | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | Taiho Oncology, Inc. | Phase 3 | Active not recruiting | Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05973773) |
| August 1, 2023 | NCT05967689 | A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20... | Taiho Oncology, Inc. | Phase 2 | Recruiting | Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05967689) |
| July 14, 2023 | NCT05945823 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | Taiho Oncology, Inc. | Phase 2 | Active not recruiting | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma... | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05945823) |
| March 13, 2023 | NCT05765734 | A Study of TAS3351 in NSCLC Patients With EGFRmt | Taiho Oncology, Inc. | Phase 1 | Terminated | Non-Small Cell Lung Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05765734) |
| February 14, 2023 | NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | Taiho Oncology, Inc. | Phase 2 | Recruiting | Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05727176) |
| June 3, 2022 | NCT05403450 | A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With... | Taiho Oncology, Inc. | Phase 1 | Terminated | Relapsed/Refractory Peripheral T-cell Lymphoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05403450) |
| July 29, 2021 | NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Taiho Oncology, Inc. | Phase 1 | Terminated | Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04982926) |
| July 16, 2021 | NCT04965818 | Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer | Taiho Oncology, Inc. | Phase 1 | Terminated | Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04965818) |
| July 8, 2021 | NCT04953910 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | Taiho Oncology, Inc. | Phase 1 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04953910) |
| July 8, 2021 | NCT04953897 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | Taiho Oncology, Inc. | Phase 1 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04953897) |
| February 25, 2021 | NCT04770246 | TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations | Taiho Oncology, Inc. | Phase 1 | Terminated | Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline... | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04770246) |
| February 3, 2021 | NCT04737187 | Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients | Taiho Oncology, Inc. | Phase 3 | Completed | Refractory Metastatic Colorectal Cancer | 492 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04737187) |
| December 8, 2020 | NCT04657081 | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | Taiho Oncology, Inc. | Phase 1/2 | Active not recruiting | Acute Myeloid Leukemia | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04657081) |
| October 26, 2020 | NCT04601857 | Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | Taiho Oncology, Inc. | Phase 2 | Terminated | Advanced and Metastatic Urothelial Cancer | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04601857) |
| October 14, 2020 | NCT04586270 | A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer | Taiho Oncology, Inc. | Phase 1 | Terminated | Advanced or Metastatic Solid Tumors | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04586270) |
| August 11, 2020 | NCT04507503 | Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | Taiho Oncology, Inc. | Not applicable | Approved for marketing | Advanced Cholangiocarcinoma | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04507503) |
| February 25, 2020 | NCT04282668 | A Study of TAS1440 With ATRA in Subjects With r/r AML | Taiho Oncology, Inc. | Phase 1 | Terminated | Acute Myeloid Leukemia | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04282668) |
| February 5, 2020 | NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND... | Taiho Oncology, Inc. | Phase 2/3 | Recruiting | Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia | 316 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04256317) |
| December 6, 2019 | NCT04189445 | Futibatinib in Patients With Specific FGFR Aberrations | Taiho Oncology, Inc. | Phase 2 | Terminated | Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid... | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04189445) |
| September 18, 2019 | NCT04093570 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | Taiho Oncology, Inc. | Phase 2 | Enrolling by invitation | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes | 332 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04093570) |
| September 18, 2019 | NCT04093362 | Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2... | Taiho Oncology, Inc. | Phase 3 | Terminated | Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04093362) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 29 |
| Phase 1/2 | 6 |
| Phase 2 | 17 |
| Phase 2/3 | 2 |
| Phase 3 | 8 |
| Not applicable | 3 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Terminated | 21 |
| Recruiting | 7 |
| Active not recruiting | 5 |
| Approved for marketing | 2 |
| Available | 1 |
| Withdrawn | 1 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 7 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Stomach Neoplasms | 6 |
| Leukemia, Myeloid, Acute | 6 |
| Myelodysplastic Syndromes | 5 |
| Neoplasm Metastasis | 4 |
| Colorectal Neoplasms | 4 |
| Cholangiocarcinoma | 4 |
| Pancreatic Neoplasms | 3 |
| Breast Neoplasms | 3 |
| Lymphoma, Non-Hodgkin | 2 |
| Lymphoma | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Lymphoma, Mantle-Cell | 2 |
| Lymphoma, T-Cell, Peripheral | 2 |
| Hematologic Diseases | 2 |
| Renal Insufficiency | 2 |
| Carcinoma, Hepatocellular | 2 |
| Lung Diseases | 2 |
| Prostatic Neoplasms | 2 |
| Leukemia, Myelomonocytic, Chronic | 2 |
| Adenocarcinoma Of Esophagus | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Esophageal Neoplasms | 1 |
| Multiple Myeloma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Endodontics practices in the United States](https://specstream.ai/data/businesses/endodontics-practices/united-states)
- [Garage door companies in the United States](https://specstream.ai/data/businesses/garage-door-companies/united-states)
- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
- [Life insurance agencies in the United States](https://specstream.ai/data/businesses/life-insurance-agencies/united-states)
- [Neurology practices in the United States](https://specstream.ai/data/businesses/neurology-practices/united-states)
- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
